GLP-1 Agonists for MASH Fibrosis: an Overview
The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) has shifted fundamentally over the past year. With the FDA approval of resmetirom and semaglutide for advanced non-cirrhotic MASH, the question is no longer whether pharmacological intervention is possible, but which agents — and which combinations of receptor targets — will prove most effective for the fibrotic component of the disease.
A review published in Cell Reports Medicine this month surveys the emerging role of GLP-1 receptor agonists across mono, dual, and triple receptor configurations in the management of MASH-related fibrosis [PMID 42697203].
The GLP-1 foundation
The approval of semaglutide for MASH with moderate-to-advanced fibrosis established the GLP-1 receptor as a validated target in liver disease. The mechanism is thought to operate through multiple pathways: reduced hepatic de novo lipogenesis, improved insulin sensitivity, weight loss, and direct anti-inflammatory effects on hepatic stellate cells. The review notes that semaglutide’s effect on fibrosis resolution in the phase 2b trial, while modest in absolute terms, was statistically significant and dose-dependent.
Dual and triple agonists
The review devotes considerable attention to the next generation of incretin-based therapies — dual GLP-1/GIP receptor agonists (tirzepatide, which is now in phase 2 for MASH) and dual GLP-1/glucagon receptor agonists (survodutide, which has reported phase 2 MASH results). The rationale for targeting multiple receptors is that each adds a distinct mechanism: GIP may improve insulin sensitivity through adipose tissue signaling, while glucagon receptor activation directly promotes hepatic lipid oxidation and energy expenditure.
Triple agonists that combine GLP-1, GIP, and glucagon receptor agonism — such as retatrutide — are also under investigation for MASH. The preclinical rationale is that the triple mechanism may produce additive or synergistic effects on hepatic fat content, inflammation, and fibrosis. Early data from the retatrutide phase 2 program in MASH are expected to clarify whether the theoretical advantages translate into histological improvement.
The fibrosis-specific question
A key theme of the review is that fibrosis — not just steatosis or inflammation — is the histological feature most strongly associated with long-term clinical outcomes in MASH. The authors note that the evolving evidence base for incretin-based therapies in fibrosis is encouraging but still incomplete. Most trials to date have been designed around steatosis reduction as a primary endpoint, with fibrosis improvement as a secondary or exploratory measure. The question of whether multi-receptor agonism produces a fibrosis benefit beyond what GLP-1 monotherapy can achieve remains open, and the review highlights the need for trials with fibrosis as a primary outcome.
What the review leaves open
The Cell Reports Medicine review is a narrative synthesis, not a systematic review or meta-analysis, and it does not pool effect sizes across studies. Its value lies in the framework it provides: a structured comparison of the mono, dual, and triple approaches as they relate specifically to MASH fibrosis, rather than to metabolic disease in general. The receptor-by-receptor analysis of mechanism — and how each additional receptor target might contribute to the fibrosis endpoint — is a useful reference for those tracking the therapeutic landscape.
Clinical context
For readers who want the full reference records on individual GLP-1 receptor agonists — including semaglutide, tirzepatide, retatrutide, and survodutide — the Research Protocols reference archive maintains detailed monographs with supporting citations, pharmacokinetic data, and trial registrations.